Showing posts with label impact. Show all posts
Showing posts with label impact. Show all posts

Thursday, October 10, 2013

Does The Government Shutdown Impact FDA Inspections?


How Does the Government Shutdown Impact FDA Inspections? | FDAzilla Blog:

"Nonetheless, in no way does this mean to let down your guard.

When we get in the inspections data, we’ll have a clearer picture of what’s really going on. As you can see, the FDA is definitely already on pace for a slower year in terms of inspections and 483s."

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
SkillsPlus Intl Info Blog

The Exemptee Institute

The Designated Representative Institute

The Health, Drug, Prescription, and GMP Supersite Gift Store 





Wednesday, May 4, 2011

Entertaining Healthcare Reform Animated Video Primer

This is really great stuff.  I have no patience to digest pages and pages of healthcare reform legislation.  This fun and informative animation makes it all very entertaining and digestible.



Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors


Monday, October 18, 2010

FDA INTERPOL IMPACT IIWA Bust Almost 300 Websites

The FDA participated in an effort to bust nearly 300 websites.

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a coordinated, cooperative effort to curb online sales and distribution of counterfeit and illicit medical products. IIWA took place between October 5-12, 2010.

The IIWA is an initiative sponsored by INTERPOL, the World Health Organization's International Medical Products Anti-Counterfeiting Task Force (IMPACT), and the Permanent Forum on International Pharmaceutical Crime, as well as national health and law enforcement agencies from 40 participating countries.

The goal of the IIWA is to protect the public health by increasing the public's awareness about the dangers and risks associated with purchasing drugs and medical devices from Internet websites, to identify the producers and distributors of counterfeit or otherwise illegal pharmaceutical products or medical devices, to target these individuals or businesses with civil or criminal action, and to seize counterfeit and illegal products and remove them from the supply chain.

294 Web sites that appeared to be engaged in the illegal sale of unapproved/misbranded drugs to U.S. consumers were targeted. A total of 274 have been suspended or no longer offer pharmaceuticals for sale. The FDA is working with its foreign counterparts to address the remaining 20 Web sites which continue to offer unapproved prescription drugs to U.S. consumers.

More from the FDA:  Buying Medicines Over the Internet


cGMP basics training for newbies and seasoned staff

#FDA #GMP #cGMP #training #course #class

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

If you are looking for live, onsite, in-person delivered courses or classes, then consider the following popular courses:
Root Cause Analysis & Deviation Investigation Report Writing - cGMP Training
Our most popular course
Qualstar - Pharmaceutical Simulation - Advanced cGMP Training
Put fun back into GMP training!














SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors

Monday, September 20, 2010

FDA Guidance - Impact Resistant Lenses - Q and A

Guidance for Industry and FDA Staff - Impact-Resistant Lenses: Questions and Answers represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. As you read through the guidance, you'll find quite a number of useful hyperlinks to additional information and references.

Eyeglasses and sunglasses (eyewear) that are intended to affect the structure or function of the body or intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, are devices within the meaning of section 201(h) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(h)). These devices are subject to applicable device regulations under Title 21, Code of Federal Regulations. Impact-resistant lenses reduce the number of eye injuries from eyeglasses and sunglasses. Glass lenses, plastic lenses, or laminated glass lenses can be made impact resistant by any method. However, lenses generally must be capable of withstanding the impact test described in 21 CFR 801.410. This guidance answers questions for manufacturers, importers, and testing laboratories on such topics as test procedures, lens testing apparatus, record maintenance, and exemptions to testing.

This guidance is a revision of “Impact-Resistant Lenses: Questions and Answers (FDA 87-4002),” issued September 1987. This guidance updates answers to questions that industry and consumers frequently ask FDA about impact-resistant lenses and FDA regulation of eyewear. The revision reflects the exemption of sunglasses from the Premarket Notification (510(k)) requirement effective February 19, 1998 (21 CFR 886.5850(b)). The revised document also includes a more detailed discussion about lens blanks, semi-finished, finished, and plano lenses, as well as import procedures. The terms "eyeglasses" and "spectacles" are used interchangeably in this document.

Eyewear products regulated by FDA are commonplace in the daily lives of the vast majority of the general public. FDA believes that impact-resistant lenses are an essential component of the safe design of these devices.  The use of impact-resistant lenses in eyeglasses and sunglasses is addressed in 21 CFR 801.410.

For more information on this topic, contact the Division of Small Manufacturers, International, and Consumer Assistance (DSMICA) by phone at 1-800-638-2041, by fax at 301-847-8149, by e-mail at dsmica@fda.hhs.gov, or write to the following address:

U.S. Food and Drug Administration
Center for Devices and Radiological Health
Office of Communication, Education and Radiation Programs
Division of Small Manufacturers, International, and Consumer Assistance
10903 New Hampshire Ave.
WO66-4613
Silver Spring, Maryland 20993

#FDA #GMP #training #cGMP

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog

Wednesday, May 26, 2010

Global Drug Supply - Counterfeit Drug Debate Heats Up


One would think that it should be fairly straightforward to drive fake and counterfeit drugs out of the global drug supply chain. It turns out there are polarized viewpoints and specific interests by many involved, as reported by SecuringPharma, Counterfeit drug debate heats up at World Health Assembly.

The situation boils down to, some:
". . . countries disagree with the WHO's working definition of the term 'counterfeit', which they maintain is being confused with intellectual property rights (IPR) issues, preferring instead terms such as 'falsely labelled', 'spurious' and 'substandard'."
Return Home: http://drughealth.blogspot.com/

Saturday, May 15, 2010

IFPMA Launches 10 Principles On Counterfeit Medicines

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) hopes the The IFPMA Ten Principles on Counterfeit Medicines will highlight the full scope of the problem and demonstrate that the fight against counterfeit medicines is simply about protecting patients’ health.

In a nutshell, here are the 10 principles:
  1. Medicine counterfeiting is first and foremost a crime against patients
  2. Counterfeit medicines threaten the full spectrum of legitimate medicines.
  3. Patents have nothing to do with counterfeiting and counterfeiting has nothing to do with patents.
  4. All substandards are not counterfeits.
  5. A medicine that is authorized for marketing by one regulatory authority but not by another should not be regarded as counterfeit.
  6. Government regulatory and enforcement authorities must be fully vested with the proper power and adequately resourced to fight counterfeits.
  7. Stopping the international trade in counterfeit medicines is vital.
  8. All stakeholders across the pharmaceutical supply chain must be made aware of the health threats posed by counterfeit medicines and collaborate.
  9. Global cooperation is needed
  10. The leadership of the World Health Organization (WHO) is crucial.
More Information:
IFPMA launches Ten Principles on Counterfeit Medicines - News Release

Return Home: http://drughealth.blogspot.com/

Wednesday, June 10, 2009

FDA Website Redesigned

The FDA reports that "Through collaboration with users in testing site-wide designs, we made improvements to make FDA.gov easier and more satisfying to use." That may well be true as they describe their thinking on the redesign, About the FDA.gov Redesign - Why did FDA change its Website? Unfortunately, one unintended adverse effect impacts this blog. So, my apologies to folks who use and follow this blog . . . The FDA redesign has broken many links to FDA images, documents, and webpages. Here's to hoping they won't be redesigning the site again, any time soon. Peace.


From SkillsPlus International Inc.